Comparative cost effectiveness supports the use of meningococcal vaccine in schools after a single case.
Roberts
R J
RJ
Petrovic
M
M
D002648:Child; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage*; D012574:Schools; D013222:State Medicine; D006113:United Kingdom / Q000453:epidemiology; D026712:Value of Life
D022401:Meningococcal Vaccines